Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Conditions
Interventions
MSB0011359C
Locations
118
United States
Arizona Clinical Research Center
Tucson, Arizona, United States
Pacific Oncology Associates
Escondido, California, United States
University of California Davis Health System
Sacramento, California, United States
California Pacific Medical Center
San Francisco, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States
Start Date
August 31, 2015
Primary Completion Date
May 23, 2022
Completion Date
May 23, 2022
Last Updated
May 3, 2024
NCT06898450
NCT06658951
NCT05101070
NCT05719558
NCT06716138
NCT06307795
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions